https://orcid.org/0000-0001-7040-317X
References
- Patel MK, Goodson JL, Alexander JP, Kretsinger K, Sodha SV, Steulet C, Gacic-Dobo M, Rota PA, McFarland J, Menning L, et al. Progress toward regional measles elimination—worldwide, 2000–2019. Morbidity Mortality Weekly Rep. 2020;69(45):1700. doi:10.15585/mmwr.mm6945a6.
- World Health Organization. Global measles outbreaks. 2021 [accessed 2021 Aug 3]. https://www.cdc.gov/globalhealth/measles/data/global-measles-outbreaks.html.
- Thompson KM, Odahowski CL. The costs and valuation of health impacts of measles and rubella risk management policies. Risk Anal. 2016;36(7):1357–4. doi:10.1111/risa.12459.
- Bloom DE, Canning D, Weston M. The value of vaccination. World Econ. 2005;6:15–16.
- Ehreth J. The global value of vaccination. Vaccine. 2003;21(7–8):596–600. doi:10.1016/S0264-410X(02)00623-0.
- Ozawa S, Clark S, Portnoy A, Grewal S, Brenzel L, Walker DG. Return on investment from childhood immunization in low-and middle-income countries, 2011–20. Health Aff. 2016;35(2):199–207. doi:10.1377/hlthaff.2015.1086.
- Ayieko P, Akumu AO, Griffiths UK, English M. The economic burden of inpatient paediatric care in Kenya: household and provider costs for treatment of pneumonia, malaria and meningitis. Cost Eff Resour Alloc. 2009;7:3. doi:10.1186/1478-7547-7-3.
- Griffiths UK, Dieye Y, Fleming J, Hajjeh R, Edmond K. Costs of meningitis sequelae in children in Dakar, Senegal. Pediatr Infect Dis.
- Chang AY, Riumallo-Herl C, Perales NA, Clark S, Clark A, Constenla D, Garske T, Jackson ML, Jean K, Jit M, et al. The equity impact vaccines may have on averting deaths and medical impoverishment in developing countries. Health Aff. 2018;37(2):316–24. doi:10.1377/hlthaff.2017.0861.
- World Health Organization. Measles: key facts. 2019. https://www.who.int/news-room/fact-sheets/detail/measles.
- World Health Organization. Estimation of unit costs for general health services: updated WHO-CHOICE estimates technical background report. 2011 [accessed 2021 Jul Mar 2011. http://www.who.int/choice/cost-effectiveness/inputs/health_service/en/.
- Memirie ST, Sisay Metaferia Z, Norheim OF, Levin CE, Verguet S, Arne Johansson K. Household expenditures on pneumonia and diarrhoea treatment in Ethiopia: a facility-based study. BMJ Global Health. 2017;2(1):e000166. doi:10.1136/bmjgh-2016-000166.
- Olumide AO, Shmueli A, Omotade OO, Adebayo ES, Alonge TO, Ogun GO. Economic costs of terminal care for selected non-communicable diseases from a healthcare perspective: a review of mortality records from a tertiary hospital in Nigeria. BMJ Open. 2021;11(4):e044969. doi:10.1136/bmjopen-2020-044969.
- Ezeoke OP, Onwujekwe OE, Uzochukwu BS. Towards universal coverage: examining costs of illness, payment, and coping strategies to different population groups in southeast Nigeria. Am J Trop Med Hyg. 2012;86(1):52. doi:10.4269/ajtmh.2012.11-0090.
- Zimmermann M, Frey K, Hagedorn B, Oteri AJ, Yahya A, Hamisu M, Mogekwu F, Shuaib F, McCarthy KA, Chabot-Couture G. Optimization of frequency and targeting of measles supplemental immunization activities in Nigeria: a cost-effectiveness analysis. Vaccine. 2019;37(41):6039–47. doi:10.1016/j.vaccine.2019.08.050.
- Nigeria National Bureau of Statistics (NBS). Living Standards Survey 2018-2019. 2019. https://microdata.worldbank.org/index.php/catalog/3827.
- Riumallo-Herl C, Chang AY, Clark S, Constenla D, Clark A, Brenzel L, Verguet S. Poverty reduction and equity benefits of introducing or scaling up measles, rotavirus and pneumococcal vaccines in low-income and middle-income countries: a modelling study. BMJ Global Health. 2018;3(2):e000613. doi:10.1136/bmjgh-2017-000613.